Obviously it did. That is why the other drug companies abandoned their inhaled insulin projects.
Red flag for the F.D.A. on bioequivalence.
Even though they're 2 for 2 on their previous predictions approval isn't the issue this time. Approval with REMS and being a failure in the market place are what are relevant now.
No big pharma partner. :(
The first one was for Retinitis Pigmentosa. Potential $15 billion dollar market.
"AMBS" - Amarantus Bioscience
Patented drug, MANF.
Under a dime. Due diligence.
"AMBS" - Amarantus Bioscience - Twitter: @AmarantusBio
Currently working with Becton Dickinson to develop diagnostic test to detect early stage Alzheimer's. Potential $500M annual market.
Company's patented drug, MANF, already has two orphan indications: Retinitis Pigmentosa and in the field of diabetes.
Read the Yahoo headline news.
AMBS will be one of the top performing stocks of 2014.
Zacks has a "BUY" rating on the stock. Get in under a dime and hold it for six months. Planned uplisting to the NASDAQ this year.